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Abstract
Purpose
To identify disease-specific cytokine profile differences in the aqueous humor (AH) (other
than the vascular endothelial growth factor) between patients with dry and treated wet age-
related macular degeneration (AMD) and healthy controls.
Methods
This retrospective study drew on a case-series of patients diagnosed with dry AMD (n = 25)
and treated wet AMD (n = 19), as well as on healthy controls (no systemic therapy; n = 20)
undergoing phacoemulsification or vitrectomy. Samples of AH and serum were collected in
parallel at the beginning of surgery. The levels of 43 cytokines were simultaneously deter-
mined using the Bio-Plex®multiplex beads system. Differences between the three groups
were statistically compared using the Kruskal-Wallis H-Test after applying the Bonferroni
correction for multiple comparisons (p<0.0012).
Results
The concentrations of three cytokines were elevated in the AH of patients with dry AMD
(CXCL6; p = 0.00067) and treated wet AMD (CXCL5, CXCL6, MIG/XCXL; all p<0.001) rela-
tive to those in the healthy controls. No other differences between the three groups were
identified. The AH levels of seven cytokines (16%), including CXCL6, ranged below the
lower limit of quantitation of the assay. Without the correction for multiple comparisons
(p<0.05), the levels of 31 of the 43 cytokines in the AH of patients with AMD would have dif-
fered significantly from those in the control. The systemic cytokine profiles (serum) were
similar in all three groups.
Conclusions
No systematic differences in the AH cytokine environment were identified between patients
with dry AMD and those with treated wet AMD. This finding might indicate that AMD is either
the result of a persistent imbalance in the physiological tissue milieu, or that the localized
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process induces no significant change in the cytokine environment of the anterior ocular
segment.
Introduction
Age-related macular degeneration (AMD), particularly advanced stages of the disease, such as
choroidal neovascularization (CNV) and geographic atrophy (GA), is the most common cause
of irreversible vision loss in elderly individuals [1, 2, 3].
In clinical terms, the distinction between “wet” and “dry” forms of the disease is based
upon the manifestation of either CNV or atrophy of the retinal pigment epithelium (RPE), the
choriocapillaris and the overlying photoreceptors, respectively [4, 5]. Despite its convenience,
this dichotomization does not reflect the continuum of the underlying progressive pathology
of the macula with advanced age. Whereas wet AMD can be impeded (to a certain degree) by
intravitreal treatment with the anti-vascular endothelial growth factor (anti-VEGF), the dry
AMD component of the disease cannot be therapeutically influenced which indeed seems to
be somewhat clinically distinct [1, 4, 6, 7]. However, the underlying reason for the switch
towards either the atrophic, dry or the neovascular, wet form of the disease is not fully under-
stood [8]. Since wet AMD is typically preceded by more or less prominent changes that are
attributed to dry AMD, its presence could be considered as a risk factor [7]. Furthermore,
advanced manifestations of both dry and wet AMD may coexist in the same eye, which argues
in favor of a continuous rather than a dichotomatous process [7, 9]. Correspondingly, there
exist significant overlaps in the mechanisms that underlie these seemingly disparate clinical
conditions [4, 10], which is not a surprising finding for such a multifactorial disease [2] that is
influenced by aging, oxidative stress, mitochondrial dysfunction, environmental factors and
chronic, age-related low-grade inflammation [1]. Close correlations between AMD and vari-
ous immunological/inflammatory gene polymorphisms have been reported, thereby suggest-
ing the involvement of immune mediated processes (e.g., complement activation) and
inflammation [2]. Changes in the cytokine and chemokine concentrations at both the local
and the systemic levels, predominantly in patients with wet AMD, have been also documented
[1, 11–17]. These cytokines appear to play an integral role in the initiation, perpetuation or
subsequent down-regulation of the immune response, eventually leading to wound healing by
the formation of a fibrotic scar [18, 19]. Correspondingly, histological investigations in eyes
with early AMD (e.g., drusen) have revealed chronic inflammation at the RPE/choroidal inter-
face [20]. Furthermore immunocompetent cells, such as lymphocytes and macrophages [3, 21,
22], have been observed in chorioretinal tissue that had been derived from eyes with wet AMD
[2]. Generally, the molecular mechanisms that underline the development and progression of
CNV, the hallmark of wet AMD, are better understood than those that are involved in the evo-
lution of the dry form of the disease [23, 24].
It has been postulated that in the aging eye, the dysregulation of reparative (para-)inflam-
matory mechanisms, particularly the down-regulation of pro-inflammatory cytokines and the
up-regulation of anti-inflammatory cytokines by the RPE [e.g., in response to stimulation by
the deposition of advanced glycation end products (AGEs)] [25], might induce and perpetuate
the low-grade chronic inflammatory process that contributes to the progression of AMD [1].
However, whether these factors are the cause or the effect of the low-grade inflammation that
is associated with the progression of AMD remains to be determined [2, 6, 26].
In an attempt to understand the pathological process, changes in many different cytokines
compared to healthy controls have been reported [6, 27]. Since the role of the abundancy of a
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single agent in the pathogenesis of AMD is difficult to estimate, we monitored and compared
cytokine environmental changes by a maximally broad panel of 43 inflammatory and pro-
fibrotic biomarkers in the aqueous humor (AH) and sera of patients with dry and treated wet
AMD and in healthy controls. By implementing the Bonferroni correction for multiple com-
parisons, we endeavored to identify the most relevant beyond all significant intergroup
changes in this context.
Patients and methods
Patients
This retrospective case series included patients with either dry or treated wet AMD or healthy
controls without any relevant systemic or ocular disease (apart from senile cataract or macular
hole (MH)), who were scheduled for phacoemulsification surgery and/or vitrectomy. Clinical
data regarding ophthalmologic and systemic diagnoses and findings, systemic and local medi-
cations, as well as duration of the ocular symptoms (e.g., visual distortion, if manifested) were
collected. For the purpose of this study, the preoperative Snellen’s best-corrected visual acuity
(BCVA) was converted into Early Treatment Diabetic Retinopathy Study (ETDRS)-letter
scores (with 85 letters representing a BCVA of 1.0). Samples of blood serum and AH were col-
lected at the beginning of ocular surgery at the Berner Augenklinik am Lindenhofspital,
between August 2013 and January 2016. The grading of macular changes was based upon clini-
cal findings and OCT diagnostics in dependence on the Clinical Age-Related Maculopathy
Staging System (CARMS) [28]. The following stages were distinguished: healthy controls (no
chorioretinal changes), dry AMD (15 intermediate drusen or any large drusen, no intra- or
sub-retinal fluid or hemorrhages), and treated wet AMD (signs of exudative AMD, such as
serous retinal detachments, non-drusenoid RPE detachments, CNV with sub-RPE or subret-
inal exudations or fibrosis prior to the onset of anti-VEGF therapy, or the presence of scars
consistent with AMD-treatment) [28].
Exclusion criteria included a history of systemic malignant, vascular or inflammatory co-
morbidities, namely, diabetes mellitus or rheumatic diseases; a history of any previous intraoc-
ular surgery or ocular trauma in the affected eye or of intraocular inflammation; the presence
or history of vitreal/(sub-)retinal hemorrhage; any ocular vascular occlusive disease; or myopia
of more than 6 diopters.
The informed and written consent of all individuals concerned was obtained, in strict
accordance with the tenets of the Declaration of Helsinki. The present study was approved by
the local Ethics Commission of the University of Bern in Switzerland (reference number: 152/
08).
Collection of aqueous humor
Samples of aqueous humor were collected at the onset of phacoemulsification surgery. About
150 to 200 microliters of undiluted aqueous humor was obtained via aspiration through a
30-gauge needle. The samples were stored within 4 hours at -20˚C for maximally 2 months
and thereafter at -80˚C until the time of the analysis.
Cytokine analysis
Within four hours of collection, the aliquots of AH and serum were frozen at -20˚C and stored
at this temperature for up to two months, thereafter at -80˚C until the time of analysis, which
was conducted simultaneously for all samples.
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The Bio-Plex1 multiplex immunoassay beads system (Bio-Plex 100 array reader and Bio-
Plex Manager software, version 6.1, Bio-Rad, Hercules, CA, USA) was used to simultaneously
quantify the concentrations of 43 cytokines and chemokines according to the manufacturer
instructions, as previously described [18]. A concentration standard was run in parallel on
each test plate. It represented the average of triplicate standard dilutions of each corresponding
chemokine/cytokine. A standard curve was generated and the sample concentrations were
determined by curve-fitting. The assays were performed in a blinded manner by an experi-
enced technician [29].
Statistical analysis
Quantitative data are presented as mean values together with the standard deviation (SD).
According to the standard curve, the lower limit of quantitation (LLOQ) of the assay working
range was typically about 1 pg/ml (http://www.biorad.com). The concentrations of several
cytokines ranged below the curve fit of the standards (out of range). To avoid a bias that would
have been introduced by excluding these values, they were set at half of the lowest quantified
level for the particular cytokine in question. Outliers were identified by a box-plot analysis
(box-whisker plot). Extreme outliers (viz., values that lay 3 box-lengths beyond the box-edges)
were excluded from the statistical analysis.
To ascertain whether or not the data were normally distributed the Shapiro-Wilk test was
applied. Since the data did not meet the criteria of a normal distribution, the non-parametric
Kruskal-Wallis H-Test was applied for the intergroup comparisons, using the level of statistical
significance of p0.05. To counteract the Type I error that was attributable to the multiple
comparisons, the Bonferroni correction was implemented to the level of significance, which
resulted in a critical value for significance of p<0.0012 [30]. The statistical analyses were per-
formed using the open source software R (Version 3.3.2–2016 RStudio, Inc.; psych package)
and SPSS (version 23.0; IBM SPSS Statistics, Armonk, NY, USA) [18, 29].
Results
Patients
The analysis included 64 eyes from 64 patients. They were allocated to one of three groups:
healthy controls (n = 20); dry AMD (n = 25); treated wet AMD (n = 19; Table 1). The patients
with dry AMD and those with treated wet AMD were of similar age (p>0.05), whereas healthy
controls were younger (p = 0.0005). The proportion of females was higher than that of males
in each group (63.2% to 76.0%; chi-square test: p = 0.65).
The BCVAs of the healthy controls and of the patients with dry AMD differed from those
of the individuals with treated wet AMD (p = 0.002 and p = 0.02, respectively). The central
retinal thickness (CRT) and choroidal thickness were similar in all groups (p>0.10 for all
comparisons).
Table 1. Demographics: Patient characteristics and clinical data for the corresponding groups.
Baseline characteristics Healthy controls Dry AMD Treated wet AMD
Number of participants, n (%) 20 (31.2) 25 (39.1) 19 (29.7)
Number of females, n (%) 14 (70.0) 19 (76.0) 12 (63.2)
Age at sample collection, y mean (SD) 74.7 (5.6) 83.5 (6.9) 84.9 (5.1)
Best-corrected visual acuity, ETDRS-letter score, mean (SD) 68.2 (11.2) 61.8 (19.7) 46.9 (22.0)
Central retinal thickness, μm, mean (SD) 237.8 (30.3) 226.2 (46.3) 236.5 (63.9)
Choroidal thickness, μm, mean (SD) 172.5 (59.3) 142.4 (56.7) 147.8 (61.2)
https://doi.org/10.1371/journal.pone.0203337.t001
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In patients with treated wet AMD, the mean time that elapsed between the last anti-VEGF
injection and the collection of the samples was 14.9 ± 20.9 months. No differences in the cyto-
kine levels were observed between patients who had received the last anti-VEGF injection
within 6 months prior of the collection of the samples and those who had received the injec-
tion heretofore.
Cytokine analysis
The concentrations of the different cytokines in the AH (pg/ml) spanned a broad range
(Tables 2 and 3).
After application of the Bonferroni correction, the AH-concentrations of most of the cyto-
kines (n = 40) (in particular CCL21, CXCL13, CCL27, CCL11, CCL24, CCL26, CX3CL1,
GM-CSF, CXCL1, CXCL2, CCL1, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8/CXCL8, IL-10, Il-16,
CXCL10, CXCL11, CCL2, CCL8, CCL7, CCL13, CCL22, MIF, CCL3, CCL15, CCL20, CCL19,
CCL23, CXCL16, CXCL12, CCL17, CCL25, TNF-α, TGF-β1, TGF-β2, and TGF-β3) were sim-
ilar in all three groups [healthy controls, dry AMD and treated wet AMD (p>0.0012)].
Eyes with treated wet AMD exhibited the highest absolute AH-concentrations in 31 of the
43 analyzed cytokines (72%). In the dry AMD group, the AH-concentrations of CXCL5,
CCL11, CCL24, GM-CSF, IL-4, CCL2, CCL13, MIF, CCL19, CCL17, TGF-β2, and TGF-β3
were higher than those in either the healthy controls or the eyes with treated wet AMD (Fig 1,
Table 2).
The concentrations of three cytokines were 1.7 to 72.8-fold higher (p<0.0012) in patients
with either dry AMD [CXCL6 (p = 0.00067)] and/or treated wet AMD [CXCL5 (p = 0.00099),
CXCL6 (p = 0.00067), MIG/CXCL9 (p = 0.00019)] than in the healthy controls, with signifi-
cant intergroup differences being registered after the application of the Bonferroni correction
(Fig 2, Table 3).
No intergroup differences in the AH-concentrations of the cytokines were observed
between eyes with dry AMD and those with treated wet AMD (all p>0.01).
CXCL6 and CCL7 were the only cytokines whose AH-concentrations increased with pro-
gression of age (p = 0.0006439 and p = 0.0006956, respectively; other cytokines: p>0.0012).
In no instance were any intergroup differences observed in the serum concentrations of the
monitored cytokines [p>0.0012 (Tables 4 and 5)]. The cytokine concentrations were 1.2 to
5775.6-fold higher in the serum than in the corresponding AH samples with the following
exceptions: CXCL5 (dry AMD only), GM-CSF, CCL2, TGF-β1 (healthy controls only), TGF-
β2 and TGF-β3. No age-correlated changes in any of the cytokines were identified in the
serum samples (p>0.0012).
Discussion
Our results revealed an upregulation of CXCL5, CXCL6 and MIG/CXCL9 (p<0.0012) in the
AH of eyes with dry and stable treated wet AMD, when compared to healthy controls. These
were the only cytokines whose up-regulation remained significant after the application of the
Bonferroni correction for multiple comparison. Heretofore, an additional 31 cytokines had
qualified for this designation when considering a level of significance of p<0.05. These find-
ings indicate that an analysis of the level of a single cytokine in clinical samples may suffer
from the weakness of attempting to detect and interpret a single point change in the complex
pathomechanism of AMD. Furthermore, it is challenging to estimate modulations in the local
cytokine environment/milieu at the lesion site by specimens taken from the anterior ocular
compartment rather than from where the pathology actually takes place. It remains a matter of
speculation whether or not the AH is indeed representative of the relatively small volume of
Cytokine profiles in dry and wet AMD
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Table 2. Mean concentrations (pg/ml) and standard deviations (SD) of the 43 monitored cytokines in the aqueous humor of healthy controls and of patients with
either dry or treated wet age-related macular degeneration (AMD).
Cytokine Healthy controls Dry AMD Treated wet AMD Assay Working Ranges
Mean (pg/ml) SD Mean (pg/ml) SD Mean (pg/ml) SD LLOQ (pg/ml) ULOQ (pg/ml)
CCL21 976.6 931.2 1’617.3 1’100.1 2’014.8 1’627.1 21.9 3’923
CXCL13 0.6 1.9 0.3 0.5 0.9 1.8 0.7 1’200
CCL27 0.3 1.3 0.4 1.3 1.9 3.4 1.2 5’000
CXCL5 47.0 74.6 3’419.0 14’656.2 635.9 2’162.5 7.3 120’000
CCL11 5.8 4.4 8.9 8.9 8.2 3.9 1.5 3’859
CCL24 11.8 11.4 42.3 93.8 18.4 9.9 6.2 4’073
CCL26 4.1 4.6 7.7 6.7 10.9 10.2 0.9 12’109
CX3CL1 33.8 20.7 51.7 38.2 55.5 34.9 4.0 11’463
CXCL6 0.1 0.0 0.3 0.3 0.7 1.2 0.8 11’135
GM-CSF 49.2 25.9 93.7 87.1 67.8 33.7 5.3 35’000
CXCL1 28.4 21.1 45.8 35.7 48.3 16.5 3.1 7’024
CXCL2 1.8 1.0 3.1 2.9 3.7 2.5 4.6 13’257
CCL1 9.4 7.7 16.6 8.8 19.1 10.9 1.8 1’015
IFN-γ 3.0 3.4 7.7 7.7 8.7 7.3 2.3 20’236
IL-1β 0.5 0.4 0.8 0.6 1.1 0.7 0.4 7’000
IL-2 0.9 1.1 1.1 1.2 1.3 0.9 0.8 13’000
IL-4 0.6 1.4 15.4 58.7 6.3 16.2 1.2 4’804
IL-6 4.7 7.1 3.4 1.8 4.9 3.8 0.7 12’000
IL-8/CXCL8 3.6 2.9 4.5 2.5 6.1 3.0 0.5 7’640
IL-10 2.3 3.9 4.6 7.2 6.2 6.8 1.3 18’708
IL-16 4.3 5.7 9.2 9.8 14.3 10.7 2.1 34’000
CXCL10 41.0 40.9 58.9 72.2 122.0 112.2 1.6 7’714
CXCL11 1.3 2.0 2.6 2.7 4.5 4.6 0.1 2’298
CCL2 300.0 102.6 351.0 336.9 340.9 87.3 0.3 4’812
CCL8 2.3 2.2 4.5 4.7 5.7 3.5 0.3 4’056
CCL7 3.1 4.6 7.7 13.4 12.5 15.0 1.9 20’133
CCL13 0.5 0.4 1.8 3.6 1.2 0.8 0.2 3’368
CCL22 6.8 4.6 12.3 13.2 13.4 5.9 0.9 14’649
MIF 50’207.1 96’380.3 128’907.2 363’701.7 112’391.1 116’068.9 23.1 377’721
MIG/CXCL9 7.5 12.3 32.1 59.2 81.0 119.5 1.8 19’600
CCL3 0.8 0.7 1.3 0.9 1.6 1.1 0.4 1’543
CCL15 296.3 182.7 409.9 358.1 554.0 396.6 1.7 9’100
CCL20 2.9 3.1 3.2 4.4 4.6 5.7 0.3 4’675
CCL19 2.4 2.6 5.7 10.9 5.2 5.1 3.0 48’494
CCL23 5.8 5.1 13.0 12.0 13.5 10.2 1.0 14’450
CXCL16 490.7 198.4 459.1 266.2 539.9 221.7 0.5 2’867
CXCL12 82.0 60.1 107.9 107.9 162.6 148.0 8.3 115’730
CCL17 0.2 0.3 1.4 5.2 0.4 1.3 1.7 430
CCL25 117.2 153.3 243.5 444.7 260.2 196.6 20.6 114’493
TNF-α 5.0 3.3 9.5 7.0 10.6 6.5 0.9 13’879
TGF-β1 80.6 132.4 129.1 215.8 165.5 135.4 1.7 27’616
TGF-β2 1’288.5 738.0 1’761.9 450.0 1’742.4 831.7 14.7 30’080
TGF-β3 6.0 11.9 9.7 14.2 7.5 8.5 2.8 15’031
LLOQ: Lower limit of quantitation; ULOQ: Upper limit of quantitation
https://doi.org/10.1371/journal.pone.0203337.t002
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Table 3. P-values appertaining to the 43 monitored cytokines in the aqueous humor of healthy controls and of patients with either dry or treated wet age-related
macular degeneration (AMD).
Cytokine Kruskal-Wallis H-Test Kruskal-Wallis H-Test Kruskal-Wallis H-Test
Healthy controls vs. Healthy controls vs Dry AMD vs.
Dry AMD Treated wet AMD Treated wet AMD
CCL21 p = 0.034 p = 0.034 p = 0.69
CXCL13 p = 0.1546 p = 0.0082 p = 0.0113
CCL27 p = 0.075 p = 0.029 p = 0.118
CXCL5 p = 0.00265 p = 0.00099 p = 0.26924
CCL11 p = 0.13 p = 0.11 p = 0.57
CCL24 p = 0.0035 p = 0.0609 p = 0.0609
CCL26 p = 0.0079 p = 0.0079 p = 0.2915
CX3CL1 p = 0.041 p = 0.041 p = 0.67
CXCL6 p = 0.00067 p = 0.00067 p = 0.10159
GM-CSF p = 0.0014 p = 0.0866 p = 0.1096
CXCL1 p = 0.084 p = 0.015 p = 0.245
CXCL2 p = 0.0036 p = 0.0025 p = 0.0812
CCL1 p = 0.0093 p = 0.0093 p = 0.5295
IFN-γ p = 0.02 p = 0.019 p = 0.529
IL-1β p = 0.059 p = 0.008 p = 0.126
IL-2 p = 0.533 p = 0.067 p = 0.261
IL-4 p = 0.0091 p = 0.0093 p = 0.9518
IL-6 p = 0.39 p = 0.31 p = 0.68
IL-8/CXCL8 p = 0.082 p = 0.019 p = 0.082
IL-10 p = 0.086 p = 0.016 p = 0.129
IL-16 p = 0.0829 p = 0.0023 p = 0.0773
CXCL10 p = 0.784 p = 0.0078 p = 0.022
CXCL11 p = 0.0127 p = 0.0031 p = 0.169
CCL2 p = 0.66 p = 0.17 p = 0.1
CCL8 p = 0.0424 p = 0.0026 p = 0.0698
CCL7 p = 0.012 p = 0.002 p = 0.135
CCL13 p = 0.0048 p = 0.0014 p = 0.5613
CCL22 p = 0.0607 p = 0.0028 p = 0.0773
MIF p = 0.222 p = 0.023 p = 0.222
MIG/CXCL9 p = 0.06656 p = 0.00019 p = 0.02358
CCL3 p = 0.0218 p = 0.0048 p = 0.1441
CCL15 p = 0.081 p = 0.023 p = 0.081
CCL20 p = 0.91 p = 0.65 p = 0.65
CCL19 p = 0.72 p = 0.61 p = 0.61
CCL23 p = 0.014 p = 0.0059 p = 0.4767
CXCL16 p = 0.38 p = 0.56 p = 0.36
CXCL12 p = 0.982 p = 0.024 p = 0.056
CCL17 p = 0.2 p = 0.2 p = 0.62
CCL25 p = 0.0869 p = 0.0051 p = 0.0972
TNF-α p = 0.0057 p = 0.0057 p = 0.5613
TGF-β1 p = 0.16 p = 0.04 p = 0.16
TGF-β2 p = 0.0037 p = 0.1705 p = 0.6544
TGF-β3 p = 0.16 p = 0.16 p = 0.81
https://doi.org/10.1371/journal.pone.0203337.t003
Cytokine profiles in dry and wet AMD
PLOS ONE | https://doi.org/10.1371/journal.pone.0203337 August 29, 2018 7 / 17
the macular RPE/Bruch’s membrane complex. Likely, only the most abundant changes in the
cytokine concentrations at the lesion site will be detectable in the constantly renewing AH.
This circumstance may partially explain why the number of cytokines for which intergroup
differences were detected was not larger than it was. The three that qualified for this distinc-
tion, namely, CXCL5, CXCL6 and MIG/CXCL9, probably figure in a true disease-associated
effect. Interestingly, the differences in their concentrations were between the healthy controls
and the two pathological sub-groups, not between the two forms of the AMD pathology. This
finding and the fact that no systematic change in the cytokine environment was detected
between dry AMD and treated stable wet AMD (Fig 1) suggests that a persistent imbalance in
the local milieu might exist in this disease, with smooth transitions occurring between dry and
wet AMD pathogenesis [4]. However, the fact that we investigated samples of treated stable
wet AMD leads to the speculation that we looked at an inactive state of the disease with possi-
ble cytokine downregulation. Nevertheless, CNV reactivation is possible at any time so that it
might be at least partially similar to the situation prior to the primary activation of the lesion.
Inflammatory activity at a subclinical level could indeed figure in AMD, in analogy to the
situation that is observed in the pseudoexfoliation syndrome, which is another age-dependent
degenerative disease with an inflammatory background. This postulate fits well with the con-
cept of inflammaging or immunosenescence, an age-related inflammatory response to aging
changes, found in many organs [31–37]. Since aging is the strongest risk factor for the develop-
ment and progression of AMD, the existence of a link between the pathogenesis of the disease
and local immunosenescence is very likely [2, 38].
In the ocular tissue of patients with AMD, an accumulation of T-cells has been observed.
Consequently, it has been proposed that lymphocytes may play a pivotal role in the breakdown
of Bruch’s membrane, in RPE-atrophy and in the onset CNV in early and late stages of AMD
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continuous data as a line graph permits an improved estimation of concentration changes not only for individual
cytokines (points) but also for the cytokine environment as a whole.
https://doi.org/10.1371/journal.pone.0203337.g001
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[39, 40]. Monokine induced by interferon-gamma (-γ) (MIG/CXCL9), which was up-regulated
in treated wet AMD, is known to be a crucial chemokine in many inflammatory processes,
particularly in those that are mediated by T-cells [41]. It is specific for T-cell chemotaxis and
cell attraction and was found to be overexpressed in the RPE/Bruch’s membrane/choriocapil-
laris complex of aging mice [42]. Although our sample number may have been too small to
detect age-related changes in in the concentrations of MIG/CXCL9 within the AH or the
serum, Torres and coworkers recently described serum MIG/CXCL9 levels to increase with
progression of age by using a large population-based cohort study [43, 44]. Shi and colleagues
reported that MIG/CXCL9, interferon-γ inducible protein 10-kDa (IP-10, CXCL10), and
interferon-γ inducible T-cell alpha (α) chemoattractant (I-TAC, CXCL11) are expressed in
RPE [45]. However, the specific functions of these chemokines in angiogenesis remain to be
determined [45–48]. As an indicator of its clinical relevance, Jonas et al. reported an associa-
tion between the severity of retinal edema and elevated concentrations of MIG/CXCL9 [13].
CNV, on the other hand, does not appear to be driven primarily by inflammatory activity,
since a relevant effect was not detected in AMD-patients who had undergone treatment with
corticosteroids in addition to anti-VEGF therapy in a prospective randomized clinical trial
[49].
The finding that elevated levels of MIG/CXCL9 were apparent only in treated wet AMD
could suggests that this change is not only age-related [43, 44], but also a marker of retinal dis-
eases with inflammatory components such as AMD [50] at a late, steady-state stage, which
deserves further attention.
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Fig 2. Mean concentrations (pg/ml) of the three cytokines/chemokines CXCL5, CXCL6 and MIG/CXCL9 in the aqueous humor of patients with either dry age-
related macular degeneration (AMD) or treated wet AMD showing relevant differences (, p<0.0012) in their levels when compared to healthy controls. Whiskers
represent the standard error of the mean. Values are represented on a logarithmic scale.
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Table 4. Mean concentrations (pg/ml) and standard deviations (SD) of the 43 monitored cytokines in the sera of healthy controls and of patients with either dry or
treated wet age-related macular degeneration (AMD).
Cytokine Healthy controls Dry AMD Treated wet AMD Assay Working Ranges
Mean (pg/ml) SD Mean (pg/ml) SD Mean (pg/ml) SD LLOQ (pg/ml) ULOQ (pg/ml)
CCL21 7’971.5 2’008.0 14’357.7 17’653.8 19’630.5 18’509.2 21.9 3’923
CXCL13 23.3 13.1 33.1 25.4 35.1 25.3 0.7 1’200
CCL27 1’612.3 428.2 2’293.4 1’188.6 2’587.4 1’177.7 1.2 5’000
CXCL5 724.7 274.1 1’217.4 1’155.9 1’374.2 1’039.9 7.3 120’000
CCL11 48.4 9.5 57.5 24.1 76.2 36.6 1.5 3’859
CCL24 371.6 196.3 584.0 560.2 433.0 250.9 6.2 4’073
CCL26 42.0 14.1 49.9 44.6 63.9 49.4 0.9 12’109
CX3CL1 166.2 46.7 242.0 152.0 271.7 179.3 4.0 11’463
CXCL6 32.1 10.1 34.6 18.4 45.8 24.1 0.8 11’135
GM-CSF 22.9 18.4 32.9 30.0 43.5 41.3 5.3 35’000
CXCL1 318.0 63.1 328.5 117.4 365.1 98.9 3.1 7’024
CXCL2 494.4 265.4 678.3 726.3 1’083.1 982.7 4.6 13’257
CCL1 66.7 10.3 75.5 40.7 87.9 45.8 1.8 1’015
IFN-γ 63.0 22.4 74.8 46.9 93.4 50.3 2.3 20’236
IL-1β 5.2 1.7 5.0 2.2 5.3 1.9 0.4 7’000
IL-2 10.9 4.2 11.7 6.1 13.6 5.9 0.8 13’000
IL-4 44.0 6.7 52.4 25.7 56.9 28.7 1.2 4’804
IL-6 6.5 2.9 8.8 3.7 10.3 4.1 0.7 12’000
IL-8/CXCL8 10.9 7.0 20.1 27.2 37.0 45.4 0.5 7’640
IL-10 70.8 25.5 88.1 63.4 105.5 79.0 1.3 18’708
IL-16 285.1 73.9 458.9 246.4 714.5 589.4 2.1 34’000
CXCL10 191.5 116.2 483.0 1124.9 313.1 203.7 1.6 7’714
CXCL11 38.8 9.1 108.0 189.1 84.6 65.0 0.1 2’298
CCL2 60.1 14.7 81.6 51.6 95.4 56.2 0.3 4’812
CCL8 88.7 21.6 151.7 143.5 160.1 131.0 0.3 4’056
CCL7 128.3 44.5 154.6 109.4 184.0 117.8 1.9 20’133
CCL13 81.8 24.8 115.4 80.2 125.3 78.0 0.2 3’368
CCL22 1010.5 1063.4 641.5 330.4 1022.7 598.4 0.9 14’649
MIF 68’484.2 78’856.9 166’888.4 259’605.2 254’498.5 239’185.4 23.1 377’721
MIG/CXCL9 432.0 228.1 2’200.1 6’308.5 1’221.1 1’222.3 1.8 19’600
CCL3 8.1 2.7 9.9 5.9 11.2 3.6 0.4 1’543
CCL15 5’487.2 2’218.7 9’693.6 6’064.3 10’720.8 7’705.4 1.7 9’100
CCL20 18.0 12.0 19.0 13.1 18.8 9.3 0.3 4’675
CCL19 512.1 344.9 679.1 648.3 802.2 857.2 3.0 48’494
CCL23 350.4 116.7 399.1 192.6 427.0 226.1 1.0 14’450
CXCL16 580.9 155.1 689.7 277.5 857.2 394.3 0.5 2’867
CXCL12 929.8 298.2 1172.3 774.1 1’598.1 1’319.1 8.3 115’730
CCL17 206.9 160.7 275.3 283.3 344.4 421.4 1.7 430
CCL25 810.8 286.0 1’063.3 713.7 1’531.1 913.4 20.6 114’493
TNF-α 53.4 11.2 72.6 53.4 87.7 61.5 0.9 13’879
TGF-β1 13.6 0.0 205.2 376.9 273.0 548.5 1.7 27’616
TGF-β2 3.1 0.0 107.6 423.6 3.1 0.0 14.7 30’080
TGF-β3 1.5 1.9 4.6 7.1 5.0 9.2 2.8 15’031
LLOQ: Lower limit of quantitation; ULOQ: Upper limit of quantitation
https://doi.org/10.1371/journal.pone.0203337.t004
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Table 5. P-values appertaining to the 43 monitored cytokines in the sera of healthy controls and of patients with
either dry or treated wet age-related macular degeneration (AMD).
Cytokine Kruskal-Wallis H-Test Kruskal-Wallis H-Test Kruskal-Wallis H-Test
Healthy controls vs. Healthy controls vs Dry AMD vs.
Dry AMD Treated wet AMD Treated wet AMD
CCL21 p = 0.6 p = 0.6 p = 0.65
CXCL13 p = 0.36 p = 0.36 p = 0.99
CCL27 p = 0.17 p = 0.12 p = 0.51
CXCL5 p = 0.45 p = 0.45 p = 0.45
CCL11 p = 0.27 p = 0.27 p = 0.27
CCL24 p = 0.7 p = 0.7 p = 0.7
CCL26 p = 0.77 p = 0.77 p = 0.77
CX3CL1 p = 0.2 p = 0.2 p = 0.85
CXCL6 p = 1.0 p = 0.27 p = 0.27
GM-CSF p = 0.64 p = 0.64 p = 0.64
CXCL1 p = 0.69 p = 0.54 p = 0.54
CXCL2 p = 1.0 p = 0.6 p = 0.6
CCL1 p = 0.74 p = 0.74 p = 0.74
IFN-γ p = 0.54 p = 0.28 p = 0.36
IL-1β p = 0.9 p = 0.9 p = 0.9
IL-2 p = 0.77 p = 0.59 p = 0.61
IL-4 p = 0.5 p = 0.5 p = 0.71
IL-6 p = 0.174 p = 0.076 p = 0.259
IL-8/CXCL8 p = 0.29 p = 0.12 p = 0.12
IL-10 p = 0.74 p = 0.74 p = 0.74
IL-16 p = 0.076 p = 0.076 p = 0.381
CXCL10 p = 0.47 p = 0.3 p = 0.47
CXCL11 p = 0.27 p = 0.12 p = 0.51
CCL2 p = 0.41 p = 0.22 p = 0.41
CCL8 p = 0.27 p = 0.27 p = 0.68
CCL7 p = 0.79 p = 0.65 p = 0.65
CCL13 p = 0.58 p = 0.58 p = 0.61
CCL22 p = 0.48 p = 0.46 p = 0.05
MIF p = 0.213 p = 0.057 p = 0.141
MIG/CXCL9 p = 0.18 p = 0.12 p = 0.72
CCL3 p = 0.4 p = 0.14 p = 0.22
CCL15 p = 0.037 p = 0.037 p = 0.745
CCL20 p = 0.88 p = 0.88 p = 0.88
CCL19 p = 0.97 p = 0.97 p = 0.97
CCL23 p = 0.87 p = 0.87 p = 0.87
CXCL16 p = 0.3 p = 0.14 p = 0.3
CXCL12 p = 0.48 p = 0.48 p = 0.48
CCL17 p = 0.97 p = 0.97 p = 0.97
CCL25 p = 0.6 p = 0.14 p = 0.16
TNF-α p = 0.41 p = 0.41 p = 0.41
TGF-β1 p = 0.086 p = 0.086 p = 0.915
TGF-β2 p = 0.21 - p = 0.21
TGF-β3 p = 0.66 p = 0.66 p = 0.96
https://doi.org/10.1371/journal.pone.0203337.t005
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In the vast majority of our patients with wet AMD, an interval of more than 6 months had
elapsed between the last anti-VEGF injection and the time at which the samples were collected.
Hence, the influence of intravitreal anti-VEGF treatment should be negligible [51, 52].
In the context of ocular diseases, data appertaining to the neutrophil-specific pro-inflam-
matory and chemoattractive cytokines/chemokines CXCL5 (ENA-78) and CXCL6 (GCP-2)
are sparse. Both chemokines show a high homology in primary structure (chemotactic
potency: CXCL6 > CXCL5 [53]) and they both interact with CXCR-2 (CXC chemokine recep-
tor 2) [54]. The present study is one of the first to identify noticeably elevated levels of these
cytokines/chemokines in the eyes of patients with dry and/or treated wet AMD relative to the
situation in the healthy controls, which remained statistically significant even after the correc-
tion for multiple comparisons. The extent to which these increases contribute to the pathogen-
esis and/or persistence of AMD remains to be addressed.
A similar up-regulation has been reported also for late forms of the pseudoexfoliation syn-
drome with luxation of the intraocular lens [29] and in eyes with epiretinal membranes [18].
Parmar et al. reported increases in the levels of several cytokines, including CXCL5, which
have been identified as an acute stress response to intense light in immunodeficient mice with
a disrupted visual cycle and as pivotal factors in the development of retinal degeneration [55].
An association between chronic light-induced damage and AMD has been reported, and this
circumstance could account for the almost 14-fold up-regulation of CXCL5 [56]. In patients
with dry AMD and in those with treated wet AMD, CXCL6 was up-regulated relative to the sit-
uation in the healthy controls. Since the AH-levels of CXCL6 (min. 0.1 pg/ml in healthy con-
trols; max. 0.7 pg/ml in treated wet AMD) ranged below the LLOQ for the used immunoassay
system (0.8 pg/ml) the detected differences may reflect not only a true disease-based change,
but also partially measurement inaccuracies. Until this latter possibility can be excluded, an
interpretation of this finding is not possible.
Moreover, we did not observe any difference in serum cytokine profiles neither between
the three compared groups nor with progression of age within the analyzed pool of patients.
This might indicate that AMD is a local ocular process without measurable systemic cytokine
environmental changes which has already been discussed controversially (e.g., TNF-α) [57,
58]. However, an age-related low-grade systemic/generalized inflammation within a similar
degree in healthy controls and AMD patients cannot be excluded.
Beyond the limitations of this study, the healthy controls were approximately 10 years
younger than the patients with dry or treated wet AMD. A possible influence of age on the
results cannot therefore be excluded. However, since a correlation between age and the AH-
levels of the cytokines was detected in only two instances [CXCL6 (p = 0.0006) and CCL7
(p = 0.0007)] and not at all between age and the serum concentrations, any effect, if it existed,
would be marginal. Nevertheless, in future studies, an age-matched group of healthy controls
would be included to enhance the power of the intergroup differences. Given that no age-
related differences between dry and treated wet AMD were identified, the absence of inter-
group differences is probably a reliable finding. Finally, since a very robust level of significance
was employed in the present study (Bonferroni correction), only differences of high signifi-
cance (p<0.0012) were considered. Hence, we cannot exclude the possibility that some rele-
vant results might have been thereby dismissed. Nevertheless, in terms of biological relevance,
we believe that the application of such a high level of significance contributed to the strength
of our findings.
For 40 of the 43 monitored cytokines, we could identify no intergroup differences in con-
centration. Our findings respecting some of these cytokines conflict with existing data, which
reveal specific associations between their levels and the pathogenesis of wet AMD [1, 11, 13,
17, 25, 26, 48, 59–63] as well as aging [64–66], either locally in the AH or systemically in the
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blood serum. Of particular note are our findings respecting IL-4 and IL-10, which, in contrast
to existing data, were not up-regulated. An up-regulation of these two cytokines would indeed
be reasonable, since both appear to be involved in the pathogenesis of AMD [3, 11, 21, 22, 26,
59, 67–70] and the process of aging [22, 25, 64, 43]. The discrepancies between our own and
existing data may be partially explained by the circumstance that we chose to evaluate not only
individual cytokines but also the cytokine environment as a whole, which necessitated a cor-
rection for multiple comparisons. As a consequence, the concentrations of 31 of the monitored
cytokines fell below the level of statistical significance (p>0.0012). The heterogeneity of the
AMD-stages that were investigated in various published studies may also have contributed to
the different outcomes [67].
In conclusion, three of the 43 monitored cytokines (7%) were up-regulated in the AH of
AMD-patients relative to the situation in the healthy controls. No differences between dry and
treated wet AMD were identified. Our data support existing evidence that inflammatory/
immunological processes play a role in the pathogenesis of AMD. The finding that 31 of the 43
monitored cytokines (72%) were dysregulated in patients with wet AMD relative to the situa-
tion in the healthy controls at a significance level of p<0.05 affords strong evidence that data
appertaining to the concentrations of individual cytokines are barely interpretable on this sta-
tistical basis. The circumstance that the AH-levels of seven of the 43 tested cytokines (16%)
hovered below the LLOQ for the immunoassay contributes to the difficulty of interpretation.
Consequently, at the present time, estimating the specific role of these cytokines in the patho-
genesis of AMD is challenging, since a relevant effect at the tissue level of the RPE/Bruch’s
membrane/choriocapillaris complex cannot excluded in the face of existing data.
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